We are live on ! Find out more
LSTA icon

Lisata Therapeutics
LSTA

22 hedge funds and large institutions have $2.61M invested in Lisata Therapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

13% more capital invested

Capital invested by funds: $2.3M → $2.61M (+$308K)

5% more funds holding

Funds holding: 21 → 22 (+1)

0.16% more ownership

Funds ownership: 8.89% → 9.05% (+0.16%)

Holders
22
Holders Change
+1
Holders Change %
+4.76%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$19.9K
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$17.2K
3
UBS Group
UBS Group
Switzerland
+$11.3K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$8.04K
5
Renaissance Technologies
Renaissance Technologies
New York
+$6.39K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$33.4K
2
TRCT
Tower Research Capital (TRC)
New York
-$1.26K
3
Wells Fargo
Wells Fargo
California
-$161
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
1
BML Capital Management
Indiana
$988K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$640K +$8.04K +2,641 +1%
Renaissance Technologies
3
Renaissance Technologies
New York
$353K +$6.39K +2,100 +2%
BlackRock
4
BlackRock
New York
$194K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$177K +$19.9K +6,548 +15%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$60.2K +$17.2K +5,639 +48%
State Street
7
State Street
Massachusetts
$49.8K – – –
CW
8
Cook Wealth
North Carolina
$41.8K – – –
HighTower Advisors
9
HighTower Advisors
Illinois
$35K – – –
Bank of America
10
Bank of America
North Carolina
$33.7K +$167 +55 +0.6%
UBS Group
11
UBS Group
Switzerland
$12.9K +$11.3K +3,708 +370,800%
Morgan Stanley
12
Morgan Stanley
New York
$8.85K – – –
FCMT
13
Founders Capital Management (Texas)
Texas
$6.94K +$5.08K +1,667 +501%
Citigroup
14
Citigroup
New York
$4.98K +$4.37K +1,436 New
CP
15
Castleview Partners
Texas
$3.47K +$3.04K +1,000 New
TRCT
16
Tower Research Capital (TRC)
New York
$1.53K -$1.26K -413 -48%
JP Morgan Chase
17
JP Morgan Chase
New York
$56 – – –
SPIA
18
Steward Partners Investment Advisory
New York
$21 – – –
Barclays
19
Barclays
United Kingdom
$14 – – –
Wells Fargo
20
Wells Fargo
California
$3 -$161 -53 -98%
Osaic Holdings
21
Osaic Holdings
Arizona
$3 – – –
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
– -$33.4K -10,719 Closed

LSTA Hedge Fund Activity: Q2 2024 in Review

22 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q2 2024, worth a combined $2.61M — up 13% from $2.3M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new LSTA positions and 1 closed out — a net gain of 1 holder — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $19.9K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $33.4K sold.

  • 22 institutional investors held Lisata Therapeutics (LSTA) as of Q2 2024, up from 21 in Q1 2024.
  • Funds reported $2.61M of Lisata Therapeutics stock for Q2 2024, up 13% quarter-over-quarter.
  • 2 funds opened new Lisata Therapeutics positions in Q2 2024 and 1 closed out, a net change of +1 holder.
  • The largest Lisata Therapeutics buyer in Q2 2024 was Geode Capital Management, an estimated $19.9K added.
  • The largest Lisata Therapeutics seller in Q2 2024 was Susquehanna International Group, an estimated $33.4K sold.

Based on aggregated 13F filings for Q2 2024.